YOLFTbeta
Regenxbio Inc

Regenxbio Inc

RGNX · NASDAQ · Healthcare / Biotechnology

7.64USD-0.39 (-4.86%)

Price History

Full chart

Market Stats

Previous Close8.03
Open8.02
Day Range7.39 – 8.04
52-Week Range5.46 – 16.19
Volume716.12K
Market Cap488.50M
P/E (TTM)0.00
Forward P/E0.00
EPS-3.78
Dividend Yield0.00%
Beta0.93
50-Day Avg9.62
200-Day Avg10.05

About

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Curran M. Simpson M.S.
  • Employees371
  • Headquarters9804 Medical Center Drive, Rockville, MD, United States, 20850, USA
  • Websitehttps://www.regenxbio.com

Leadership

  • Mr. Curran M. Simpson M.S.President, CEO & Director · b. 1962
  • Mr. Patrick J. Christmas II, J.D.Executive VP & Chief Strategy and Legal Officer · b. 1971
  • Dr. Stephen Pakola M.D.Executive VP & Chief Medical Officer · b. 1969
  • Mr. Mitchell Chan M.B.A.Executive VP & CFO · b. 1981
  • Mr. Craig MalzahnExecutive VP of Product Development & CTO · b. 1973
  • Dr. Olivier Danos Ph.D.Executive VP & Chief Scientific Officer · b. 1958
  • Ms. Shiva G. FritschChief Communications & People Officer
  • Dr. Ram Palanki Pharm.D.Executive VP & Chief Commercial Officer · b. 1976
  • Ms. Nina HunterSVP of Global Regulatory Strategy and Quality
  • Dr. Jahannaz Dastgir D.O.Clinical Development Lead

Financials

Income Statement

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue6.09M6.12M7.59M4.59M10.39M218.50M35.23M154.57M470.35M112.72M90.24M83.33M170.44M
Growth (%)-+0.54%+23.99%-39.52%+126.48%+2002.42%-83.88%+338.70%+204.30%-76.03%-19.94%-7.66%+104.54%
Cost of Revenue324.00K1.01M1.50M959.00K1.71M9.64M8.24M35.71M51.83M54.55M37.21M33.57M20.30M
Gross Profit5.76M5.11M6.08M3.63M8.68M208.87M26.99M118.85M418.51M58.18M53.03M49.76M150.14M
Gross Margin94.68%83.55%80.19%79.10%83.56%95.59%76.61%76.89%88.98%51.61%58.76%59.72%88.09%
Operating Expense10.54M8.79M29.22M68.97M84.57M120.77M175.99M238.09M258.53M321.06M321.16M283.11M311.34M
Operating Income-4.78M-3.68M-23.14M-65.34M-75.89M88.10M-149.00M-119.23M159.98M-262.88M-268.13M-233.35M-161.20M
Operating Margin-78.46%-60.16%-304.92%-1423.84%-730.15%40.32%-422.89%-77.14%34.01%-233.20%-297.12%-280.03%-94.58%
EBITDA-4.78M-3.65M-22.71M-64.80M-73.20M92.08M-90.34M-96.83M177.09M-244.24M-239.46M-198.23M-133.25M
EBITDA Margin-78.46%-59.67%-299.30%-1411.99%-704.31%42.14%-256.40%-62.65%37.65%-216.67%-265.36%-237.89%-78.18%
Net Income-5.39M-4.00M-22.81M-62.97M-73.17M99.94M-94.73M-111.25M127.84M-280.32M-263.49M-227.10M-193.88M
Net Income Margin-88.50%-65.41%-300.62%-1372.13%-704.02%45.74%-268.88%-71.98%27.18%-248.68%-291.99%-272.54%-113.75%
R&D5.05M4.96M17.28M45.48M57.22M83.87M124.19M166.29M181.44M242.45M232.27M208.52M228.30M
R&D as % of Total Revenue82.98%81.06%227.71%991.11%550.60%38.38%352.47%107.59%38.58%215.09%257.38%250.24%133.95%
Interest Expense611.00K321.00K20.00K000107.22M771.00K26.28M23.25M6.86M12.66M45.01M
Interest Expense % of Total Revenue10.04%5.25%0.26%0.00%0.00%0.00%304.32%0.50%5.59%20.63%7.60%15.19%26.41%

Balance Sheet

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.51M3.49M221.38M172.73M198.68M543.81M497.91M708.16M1.11B833.27M573.97M465.99M453.03M
Total Liabilities4.65M9.19M4.57M10.99M15.65M34.97M47.71M330.41M349.61M317.07M262.23M206.34M350.30M
Total Equity-2.14M-5.70M216.81M161.74M183.03M508.85M450.20M377.75M764.30M516.20M311.74M259.65M102.73M
Cash1.12M1.12M54.12M24.84M46.66M75.56M69.51M338.43M345.21M96.95M34.52M57.53M34.47M
Total Debt655.00K2.40M---5.85M11.29M72.65M86.68M94.80M89.29M82.03M260.52M
Net Debt-464.00K1.28M-54.12M-24.84M-46.66M-69.71M-58.22M-265.77M-258.53M-2.15M54.77M24.51M226.05M

Cash Flow

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.01M-2.40M-22.52M-48.56M-57.99M104.65M-107.70M-54.06M218.88M-207.49M-218.41M-173.13M-123.96M
Investing Cash Flow--163.80M-163.80M19.16M-4.79M-279.36M93.56M122.76M-406.64M-11.93M190.94M103.45M-15.87M
Financing Cash Flow1.97M2.40M239.31M119.00K84.60M204.44M8.38M200.21M195.25M-28.84M-34.97M92.68M116.77M
Capital Expenditure0522.00K522.00K8.15M7.16M13.28M11.72M26.87M84.17M30.72M9.96M2.44M2.41M
Free Cash Flow-3.01M-2.40M-23.04M-56.71M-65.15M91.37M-119.42M-80.93M134.70M-238.21M-228.37M-175.56M-126.38M
Dividends Paid--000--------
FCF to OCF100.00%100.00%102.32%116.78%112.35%87.31%110.88%149.70%61.54%114.81%104.56%101.41%101.95%
Dividend Paid to FCF--0.00%0.00%0.00%--------

Earnings

Report DateNov 5, 2015Mar 3, 2016May 5, 2016Aug 9, 2016Nov 9, 2016Mar 7, 2017May 9, 2017Aug 8, 2017Nov 8, 2017Mar 6, 2018May 8, 2018Aug 8, 2018Nov 7, 2018Feb 27, 2019May 7, 2019Aug 7, 2019Nov 5, 2019Feb 26, 2020May 7, 2020Aug 6, 2020Nov 4, 2020Mar 1, 2021May 5, 2021Aug 9, 2021Nov 2, 2021Mar 1, 2022May 4, 2022Aug 3, 2022Nov 3, 2022Feb 28, 2023May 3, 2023Aug 2, 2023Nov 8, 2023Feb 27, 2024May 8, 2024Aug 1, 2024Nov 6, 2024Feb 25, 2025May 12, 2025Aug 7, 2025Nov 6, 2025Mar 5, 2026May 14, 2026Aug 6, 2026Nov 5, 2026
EPS Estimate-2.18-0.34-0.45-0.51-0.60-0.75-0.76-0.80-0.73-0.821.070.56-0.81-0.34-0.89-0.77-0.24-0.95-0.87-0.93-1.01-0.43-1.30-1.15-1.124.71-1.28-1.54-1.46-1.23-1.41-1.21-1.52-1.27-1.26-1.31-1.10-1.080.49-1.13-1.30-0.72-1.410.12-1.36
EPS Actual-1.52-0.20-0.41-0.55-0.69-0.74-0.82-0.47-0.67-0.513.040.30-0.560.11-0.89-0.83-0.94-0.72-1.08-0.910.42-1.24-1.20-1.36-1.376.67-1.79-1.58-1.75-1.38-1.53-1.66-1.41-1.43-1.34-1.05-1.17-1.010.12-1.38-1.20-1.30-1.720.43-
Surprise30.28%41.18%8.89%-7.84%-15.00%1.33%-7.89%41.25%8.22%37.80%184.11%-46.43%30.86%132.35%0.00%-7.79%-291.67%24.21%-24.14%2.15%141.58%-188.37%7.69%-18.26%-22.32%41.61%-39.84%-2.60%-19.86%-12.20%-8.51%-37.19%7.24%-12.60%-6.35%19.85%-6.36%6.86%-75.51%-22.12%7.69%-80.71%-21.99%258.33%-
TimingPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap488.50M
Enterprise Value458.20M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.26
Price / Sales2.80
Price / Book6.89
EPS-3.78
Book Value1.33
Revenue (TTM)174.48M
Gross Profit (TTM)-78.42M
EBITDA-148.78M
Profit Margin-112.58%
Operating Margin27.09%
Return on Equity-137.63%
Return on Assets-21.20%
Shares Outstanding66.01M
Shares Float57.23M
Beta0.93
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 12 analystsTarget 23.73
  • Strong Buy
    6
  • Buy
    5
  • Hold
    1

Ownership Breakdown

Institutions
65.72%
Insiders
6.55%
Retail / Other
27.73%

Top Institutional Holders

  • BlackRock Inc
    5.78M8.80%
  • Redmile Group, LLC
    4.37M6.65%
  • JPMorgan Chase & Co
    3.48M5.30%
  • State Street Corp
    2.73M4.16%
  • Morgan Stanley - Brokerage Accounts
    2.07M3.15%
  • Vanguard Capital Management, LLC
    2.01M3.06%
  • The Goldman Sachs Group Inc
    1.84M2.80%
  • Qube Research & Technologies
    1.31M2.00%
  • Geode Capital Management, LLC
    1.14M1.73%
  • AQR Capital Management LLC
    1.05M1.60%
  • Vanguard Portfolio Management, LLC
    1.02M1.55%
  • Integral Health Asset Management, LLC
    800.00K1.22%
  • Dimensional Fund Advisors, Inc.
    731.59K1.11%
  • D. E. Shaw & Co LP
    712.81K1.09%
  • Two Sigma Investments LLC
    669.81K1.02%

Top Fund Holders

  • State Street® SPDR® S&P® Biotech ETF
    2.07M3.15%
  • Vanguard MStar Total Stk Mkt Idx Invest
    1.77M2.69%
  • JPMorgan Small Cap Growth A
    1.30M1.98%
  • iShares Russell 2000 ETF
    1.25M1.91%
  • Nuveen Quant Small Cap Equity R6
    855.17K1.30%